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Abstract
Several specific assays have been developed for the measurement of etoposide in biological
fluids. As large samples are required for high sensitivity, these systems are not appropriate for
a pediatric practice. In the present study, however, an improved method for the determination
of serum levels of the anticancer drug etoposide was developed, using high-performance liquid
chromatography with fixed-wavelength ultraviolet detection. Etoposide was extracted from serum
using dichloromethane. The efficiency of extraction from serum was 85.7 +/- 7.7% for etoposide
and 81.1 +/- 8.4% for diphenylhydantoin, the internal standard. The serum concentrations of
etoposide were measured in 0.2-ml serum samples. The lower limit of detection was 50 ng/ml.
Each measurement was completed within 5 min. The linear quantitation range for etoposide was
0.05-50 microg/ml. This assay presents an alternative method for routine measurement of serum
levels of etoposide in the pediatric oncology setting.
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Several speciﬁc assays have been developed for the measurement of etoposide in biological ﬂuids. As large samples are required for high sensitivity, these systems are not appropriate for a pediatric practice. In the present study, however, an improved method for the determination of serum levels of the anticancer drug etoposide was developed, using high-performance liquid chromatography with ﬁxed-wavelength ultraviolet detection. Etoposide was extracted from serum using dichloro-
methane. The eﬃciency of extraction from serum was 85.7±7.7  for etoposide and 81.1±8.4  for diphenylhydantoin, the internal standard. The serum concentrations of etoposide were measured in 0.2-ml serum samples. The lower limit of detection was 50 ng/ml. Each measurement was completed within 5 min. The linear quantitation range for etoposide was 0.05-50μg/ml. This assay presents an alternative method for routine measurement of serum levels of etoposide in the pediatric oncology setting.
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E toposide, a semi-synthetic derivative of podophyl-lotoxin, is used in treating patients with a variety of malignant tumors［1, 2］. The cytotoxicity of etoposide is dependent serum concentrations of the drug and the duration of exposure［3］. Previous studies suggest that the steady-state concentration or the area under the concentration curve attained as a result of a continuous infusion of etoposide is related to its toxicity
［4, 5］. Recent evidence suggests that monitoring etoposide plasma concentrations could help to individual-
ize its dosage, and thus reduce hematologic toxicity while optimizing the dose intensity［6］. Several speciﬁc high-
performance liquid chromatographic(HPLC)assays have been developed over the past 15 years for the measure-
ment of etoposide in biological ﬂuids［2, 7-11］. As large samples are required for high sensitivity, these systems are not appropriate for a pediatric oncology practice. Our objective was to develop a convenient and sensitive method of HPLC that would be suﬃciently reliable for pharmacokinetic studies and for monitoring the serum levels of etoposide during the treatment of malignant disease in children.
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Materials and Methods
 
Etoposide
(Rastet?)of pharmaceutical purity was kindly supplied by Nihon Kayaku Inc. (Tokyo, Japan). Distilled water,
acetonitrile, dichloromethane, and methanol were of liq-
uid chromatographic grade (Nacalai Tesque, Kyoto,
Japan). The internal standard, diphenylhydantoin(DPH,
Nacalai), was of analytical reagent grade. Control sera were obtained from healthy volunteers. One-milliliter samples of blood for determinations of serum levels of drug were drawn into polystyrene tubes, then centrifuged at 3000 rpm for 5 min to separate the serum. Sera were stored in polystyrene tubes and frozen at－20°C until assay.
Standards and control samples were prepared from a stock solution of 1000μg/ml etoposide in a methanol-water (50:50)
solution that was added to drug-free pooled serum to give ﬁnal concentrations of 0, 0.5, 1.0, 5.0, 10.0, 15.0, and 25.0μg/ml of serum. Quality-control samples for monitoring within-run and between-run imprecision were similarly prepared but from diﬀerent stock standards.
Standards and controls were aliquoted into 1.5-ml poly-
styrene tubes and stored at－20°C until assay.
Samples for analysis were extracted as follows. A 20-μl volume of DPH at a concentration of 100μg/ml was added to 0.2 ml of serum in a 10-ml glass-stoppered centrifuge tube.
After 5 ml of dichloromethane was added, the mixture was shaken for 10 min, then centrifuged at 1500 rpm for 5 min. To another 10-ml clean glass tube was transferred 4.0 ml of the dichloromethane layer, which was evaporat-
ed to dryness at ambient temperature in a vacuum evapo-
rator. The residue was reconstituted in 100μl mobile phase of the HPLC, and was subjected to HPLC.
Chromatographic determina-
tions of etoposide and DPH were performed using a Chromatopac (Shimadzu, Kyoto, Japan) consisting of the following:an LC-6AD pump coupled to an injector,
9E(Shimadzu), with a 100-μl ﬁxed loop and an SPD-6A variable-wavelength ultraviolet detector. Data output was monitored with a C-R4A integrator.
The analytical column［ODS-M (octadecylated silica-gel column),
Shimadzu］, was 150-mm long, with an internal diameter of 6.0 mm and a particle size of 5μm. The guard column used, ODS-E (Shimadzu), was 10-mm long with an
 
internal diameter of 4.0 mm and a particle size of 5μm.
These were covered with a column heater equipped with a column oven(CTO-6A). The column ﬂow-rate was set at 1.5 ml/min, and the precolumn and column tempera-
tures were maintained at 40°C. The detection wavelength was determined at 229 nm. Analyses were performed in the mobile phase that consisted of methanol, distilled water, and acetonitrile(55:42:3, v/v/v). HPLC was performed on 20-μl serum samples.
Calibration was performed by the internal standard method. A calibration curve for etoposide was constructed by plotting the relationship between the serum concentrations of etoposide and the etoposide peak area to DPH peak-area ratios. Serum samples were prepared containing 0, 5, 10, 20, and 40
μg/ml of etoposide mixed with 100μg/ml of DPH.
The extraction eﬃcacy of etoposide and DPH was calculated by comparing the peak area obtained after injection of the theoretical amount of each compound with that obtained after injection of the extracts obtained from the serum samples.
The assay was validated by establishing within-day and between-day variations. To establish within-day variation, 5 samples sets were pre-
pared on the same day. To determine the between-day variation, the assay was repeated monthly for 6 months.
Results are presented as the mean±
S.D. Correlations were calculated by Spearman’s rank correlation test. A level of P＜0.05 was accepted as statistically signiﬁcant.
Results
 
Chromatograms of a stan-
dard sample with 50 ng/ml etoposide in solvent and extracted serum sample spiked with etoposide(2μg/ml)
showed no interference from other UV-absorbing sub-
stances (Fig. 1). This system typically gave retention times of 3.4±0.2 min for etoposide and 4.7±0.1 min for DPH. The overall chromatographic run could be carried out within 5.0 min.
The extraction eﬃciency of etoposide in serum was 85.7±7.7  at a serum concentration of 5.0μg/ml. The extraction eﬃciency of DPH, determined using etoposide as an internal standard, was 81.1±8.4  for serum.
The calibration curve showed a linear correlation between the etoposide/DPH area ratio and
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serum concentrations of etoposide(Fig. 2).
The method described showed a lower limit of detection for etoposide in serum of 50 ng/ml. The within-day variation was 4.30  in serum at levels of 0.5, 5.0, and 15.0μg/ml(n＝15).
The between-day variation was 5.46  in serum at levels
 
of 0.5, 5.0, and 15.0μg/ml(n＝18).
Discussion
 
Several HPLC methods［12］for determining serum levels of etoposide have been described since the ﬁrst report in 1981 by Strife et al.［9］. Harvey et al. have developed an assay to shorten analysis time［2］. The lower quantitation limit of their assay was 100 ng/ml for 1.0 ml of plasma. The HPLC method reported by Holthuis et al. utilized UV detection and had a limit of quantitation of 30 ng/ml［13］. Their assay required a plasma sample of as much as 1.0 ml. Boos et al.
analyzed the etoposide concentrations by HPLC, which required a serum sample of only 0.19 ml, but the detec-
tion limit was 200 ng/ml［14］. Sinkule et al. have described an HPLC method having a lower limit of detection of 20 ng/ml utilizing a plasma sample of 0.5 ml
［15］. Saita et al. have described an enzyme-linked immunosorbent assay(ELISA)for etoposide capable of measuring as little as 40 pg/ml［16］. However, as this method requires a serum sample of as much as 10 ml, it is not useful for pediatric practice. Using the combined method of liquid chromatography and mass spectrometry established by Danigel et al., blood samples of 8-10 ml are required［17］.
Although these assays may be useful for monitoring serum etoposide levels in adults, they emphasize sensitiv-
ity and simplicity, but not small sample size. They are therefore not appropriate for the detection of serum etoposide concentrations in children.
The present HPLC method was established by Fujitaka et al. for the quantitation of glucocorticoids［18］. The method can be used to determine the serum concentra-
tions of etoposide in a minimum sample size of 0.2 ml with a detection limit of 50 ng/ml. This small amount of serum can be obtained easily and relatively non invasively from infants and young children with cancer.
The lower limit of detection of 50 ng/ml in the present system was found to be adequate for sample measurement for up to 24 h following intravenous doses of etoposide within the dosage range commonly used clinically in children(＞50 mg/m?body surface area). This method requires less than 6 min to analyze one sample, which is as simple and accurate as the earlier methods.
In conclusion, in view of the reduced invasiveness and high analytical accuracy of the method described herein,
coupled with its simplicity, this assay presents an alterna-
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Fig.2  Calibration curve for etoposide in serum in which x is the concentration of etoposide(μg/ml)and y is the ratio of the peak area of etoposide to that of DPH.
Fig.1  Chromatograms of(a)a standard 50 ng/ml etoposide in solvent and extracts obtained from(b)drug-free human serum and
(c)a human serum sample with added etoposide(2μg/ml)in which x is the time(min)and y is the peak height.
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tive method for routine measurement of serum levels of etoposide in a pediatric oncology setting.
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